Por: Associated Press Health October 27, 2022
Merck turned in a better-than-expected third quarter and raised its 2022 forecast as the drugmaker’s top seller brought in over a third of its revenue. Sales of the cancer fighter Keytruda grew 20% to more than $5.4 billion in the quarter and would have jumped 26% without the impact of foreign exchange rates, Merck said Thursday.The drugmaker also saw sales for its Gardasil vaccine grow 15% to $2.3 billion. That vaccine protects against... + full article
MarketWatch USA Business October 27, 2022
“Three transactions shows deals can get done,” Litchfield says. “Where science and value align, we will act.” Merck shares were up 1.6% on Thursday, trading at a flat $100 per share, after the company that beat Wall Street expectations. Merck’s sales were $15 billion... + más
Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients | CNBC
Drugmaker Merck tops 3Q forecasts as Keytruda sales jump 20% | Associated Press
ABC News USA Business October 21, 2022
Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free.Pfizer executives said the commercial pricing for adult doses could start early... + más
Pfizer says it's eyeing a $110 to $130 list price for COVID-19 vaccine in U.S. | Fox Business
Pfizer says COVID-19 vaccine will cost $110-$130 per dose | ABC News
ABC News USA Health October 21, 2022
WPLG Local 10 USA Health October 21, 2022
The Boston Globe USA Business October 13, 2022
COVID-19 vaccine maker Moderna’s stock rose the most in two months after Merck & Co. said it would exercise an option to work in partnership with the biotech on a messenger RNA cancer vaccine.Moderna will receive $250 million from Merck in exchange for joint development and... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
RTTNews USA Health October 12, 2022
Merck & Co., Inc. (), known as MSD outside the U.S. and Canada, announced Wednesday that Health Canada has granted approval for KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at... + más
Study: Too few kids with sickle cell get stroke screen, care | Associated Press
CNBC USA Health October 12, 2022
Pipettes are seen at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, U.S., on Tuesday, Nov. 14, 2017. Moderna this week started testingAdam Glanzman Bloomberg Getty Images and will jointly develop and sell a cancer vaccine that is personalized for individual... + más
Moderna surges as Merck ramps up collaboration on cancer vaccine | The Boston Globe
About iurex | Privacy Policy | Disclaimer |